Invea Therapeutics ^{Filed Terms, Nasdaq: INAI}

We are a biotechnology company seeking to develop oral, small-molecule therapies for IMIDs. IMIDs are a diverse group of conditions — including skin or cutaneous inflammatory diseases such as chronic urticaria (commonly known as hives), atopic dermatitis, and prurigo nodularis joint or rheumatologic and connective tissue disorders, such as rheumatoid arthritis and systemic lupus erythematosus; gut or gastrointestinal diseases such as inflammatory bowel disease, including Crohn’s disease and ulcerative colitis; lung or respiratory and allergic airway conditions, such as asthma and allergic rhinitis; and autoimmune neurological diseases such as multiple sclerosis — that could result from an imbalanced or dysregulated immune response leading to chronic, multi-system or organ inflammation. We currently have two product candidates, including INVA8001, which we plan to advance into Phase 2a clinical development in the EU for chronic inducible urticaria, a debilitating skin condition. We intend to submit a CTA to the competent authorities of the relevant EU member states in the second half of 2026.